GS
NKTR icon

GTS Securities’s Nektar Therapeutics NKTR Stock Holding History

GTS Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-759
Closed -$10.6K – 4195
2024
Q1 		$10.6K Buy
+759
New +$7.95K ﹤0.01% 3717

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GTS Securities's NKTR Position: Q2 2024 in Review

GTS Securities sold out of Nektar Therapeutics (NKTR) in Q2 2024, closing a stake of 759 shares — an estimated $10.6K sold.

GTS Securities first reported a position in NKTR in Q1 2024 and held it in 1 quarter. The position peaked at $10.6K in Q1 2024. 133 funds tracked by Wall St. Rank hold NKTR as of Q2 2024.

  • GTS Securities reported no remaining Nektar Therapeutics position as of Q2 2024 after selling out during the quarter.
  • GTS Securities sold 759 Nektar Therapeutics shares in Q2 2024, an estimated $10.6K.
  • GTS Securities first reported a position in Nektar Therapeutics in Q1 2024 and held it in 1 quarter.
  • GTS Securities's Nektar Therapeutics position peaked at $10.6K in Q1 2024.
  • 133 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2024.

Based on GTS Securities's 13F filing for Q2 2024, filed 14 Aug 2024.